Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (2016 - 2025)

Cytokinetics (CYTK) has disclosed Shares Outstanding for 16 consecutive years, with $122.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding changed N/A to $122.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $122.9 million, a N/A change, with the full-year FY2025 number at $122.9 million, changed N/A from a year prior.
  • Shares Outstanding was $122.9 million for Q4 2025 at Cytokinetics, up from $122.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $122.9 million in Q4 2025 to a low of $71.6 million in Q1 2021.
  • A 5-year average of $100.1 million and a median of $96.1 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 22.5% in 2024, then increased 1.77% in 2025.
  • Cytokinetics' Shares Outstanding stood at $83.8 million in 2021, then increased by 13.13% to $94.8 million in 2022, then rose by 7.17% to $101.6 million in 2023, then increased by 15.99% to $117.9 million in 2024, then increased by 4.29% to $122.9 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Shares Outstanding are $122.9 million (Q4 2025), $122.1 million (Q3 2025), and $119.6 million (Q2 2025).